The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Timing of primary tumor resection and survival in left-sided RASwt mCRC
Ramon Salazar, MD, PhD, Institut Català D’Oncologia, Barcelona, Spain, discusses a post hoc analysis of the CR-SEQUENCE trial (EU CT: 2024-510967-41-00), which examined how the timing of primary tumor resection affects survival in patients with unresectable, left-sided, RAS wild-type metastatic colorectal cancer treated with sequential EGFR and VEGF inhibitor-based regimens. Resection performed after initiating systemic therapy was linked to longer overall and progression-free survival compared with upfront or no resection, independent of treatment sequence. These hypothesis-generating findings support further prospective evaluation of induction therapy before surgery in selected patients. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
